
|Articles|January 16, 2015
- Vol 32 No 1
- Volume 32
- Issue 1
Talk Radio, 2 am
Author(s)Richard M. Berlin, MD
I’m driving home from the ER, not ready for sleep, eaten up by memories of my mistakes...
Advertisement
I’m driving home from the ER,
not ready for sleep, eaten up
by memories of my mistakes,
a man on the radio telling me
not to worry because I can learn
to control my mind. He says
thoughts are like puppies
we can paper-train and teach
to be obedient. He says
one day that puppy will calm down,
cuddle up, and lick my face.
But who is this guy kidding?
My mind isn’t a puppy tonight-
it’s a wild tiger,
and it’s ripping out my heart.
Articles in this issue
over 11 years ago
Does TMS Hold Promise for Generalized Anxiety Disorder?over 11 years ago
Managing Anxiety in the Medically Illover 11 years ago
Mental Health Benefits of Exercise in Childrenover 11 years ago
Gone Girl by Gillian Flynnover 11 years ago
How to Fix the Broken Mental Health System: Ten Crucial Changesover 11 years ago
In With the Old, Out With the Newover 11 years ago
The Dynamics of Psychosis: Therapeutic Implicationsover 11 years ago
A Rational Suicide?Advertisement
Related to this article

Two grief experts expose the hidden health, social, and economic toll of bereavement—and the policy gaps leaving millions of grieving Americans unsupported.

Learn how the inhibition constant and 5-HT2A binding explain LSD effects—and why potent atypical antipsychotics may rapidly end a bad trip.

FDA hearing spotlights debates over psychedelic therapy: who administers, how to prove efficacy, and how to track safety as approvals near.

New US adult ADHD guidance nears publication, promising clearer diagnosis, comorbidity screening, and clinician training to curb misdiagnosis.

New research maps an mPFC–zona incerta circuit that drives punishment-resistant binge eating and hints at personalized brain stimulation targets for better treatment.

Phase 3 BLOOM tests 48-hour at-home oral brexanolone for rapid postpartum depression relief, with tighter monitoring after prior trial issues.

FDA clears Simtriyo, first NDSRI stimulant for ADHD ages 6 and older, as millions return to school—see what this means for treatment.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Vol 43, Issue 9 - Interactive
2
FDA Hearing on Psychedelic Medicine Reveals a Field Divided on the Road to Approval
3
Insights on the New Adult ADHD Guidelines: A Conversation With the President of APSARD
4
Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression
5

